Kesem Health announced today it succeeded in securing a place in Australian’s only mid-stage digital health program, ANDHealth+.
Kesem Health will receive up to $60,000 worth of specialist third-party services and up to $150,000 of in-kind support to enhance their ability to penetrate global markets and raise significant growth capital. No transfer of equity or intellectual property rights is required to participate in the ANDHealth+ program.
ANDHealth+ provides mid-stage digital health companies with support from proven experts to undertake a significant piece of work focused on securing the clinical and/or commercial evidence to enhance investment readiness and progress market entry strategy.
Kesem Health was selected together with four other companies into the 2018 cohort. A highly experienced industry selection panel chose from 42 high quality submissions from across Australia. The announcement was made by The Hon. Philip Dalidakis MP, Minister for Trade and Investment, Innovation and the Digital Economy, and Small Business.
“The ANDHealth+ program will support Kesem Health’s continued progress in the commercialisation of our novel technology. It also complements the FDA-clearance of the iUFlow™ solution and the company’s effort working towards a CE Mark for the utilization of the iUFlow™ solution in the EU market”, said Kesem Health’s CEO, Gil Hidas.
Bronwyn Le Grice, Managing Director and CEO of ANDHealth said: “We are excited to be working with Kesem Health over the next months to bring their evidence-based technologies closer to market and investment readiness. ANDHealth fills a crucial gap in the Australian commercialisation landscape that would otherwise leave companies like Kesem Health without expert support and guidance to progress their technology.”